Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)

Main Article Content

Gordon Sussman
Jacques Hebert
Wayne Gulliver
Charles Lynde
William H Lang
Olivier Chambenoit
Gretty Deutsch
Frederica DeTakaosy
Lenka Rihakova

Keywords

omalizumab, urticaria, chronic urticaria

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Novartis.

 

Copyright 2018 SKIN